In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II)

Abstract

The aim of the present investigation was to develop matrix tablet formulations for the in vitro controlled release of two new tuberculocidal adamantane aminoethers (compounds III and IV), congeneric to the adamantane derivative SQ109, which is in final clinical trials, and aminoethers (I) and (II), using carefully selected excipients, such as polyvinylpyrrolidone, sodium alginate and lactose. The tablets were prepared using the direct compression method and dissolution experiments were conducted using the US Pharmacopoeia type II apparatus (paddle method) in gastric and intestinal fluids. The results suggest that both analogues, albeit more lipophilic than SQ109, and aminoethers (I) and (II), have the requisite in vitro release characteristics for oral administration. In conclusion, these formulations merit further assessment by conducting in vivo studies, at a later stage.

Key words

adamantane aminoethers - tuberculosis - matrix tablet formulations - in vitro release

• References

• 1 Nemecek J, Sychra P, Machacek M. et al. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur J Med Chem 2017; 130: 419-432
• 2 Chetty S, Ramesh M, Singh-Pillay A. et al. Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett 2017; 27: 370-386
• 3 Khanapur M, Alvala M, Prabhakar M. et al. Mycobacterium tuberculosis chorismate mutase: A potential target for TB. Bioorg Med Chem 2017; 25: 1725-1736
• 4 Nefzi A, Appel J, Arutyunyan S. et al. Parallel synthesis of chiral pentaamines and pyrrolidine containingbis-heterocyclic libraries. Multiple scaffolds with multiple building blocks: A double diversity for the identification of new antitubercular compounds. Bioorg Med Chem Lett 2009; 19: 5169-5175
• 5 Scalacci N, Brown AK, Pavan FR. et al. Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis. Eur J Med Chem 2017; 127: 147-158
• 6 Pulipati L, Yogeeswari P, Sriram D. et al. Click-based synthesis and antitubercular evaluation of novel dibenzo [b,d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages. Bioorg Med Chem Lett 2016; 26: 2649-2654
• 7 Matviiuk T, Madacki J, Mori G. et al. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. Eur J Med Chem 2016; 123: 462-475
• 8 Protopopova M, Hanrahan C, Nikonenko B. et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-974
• 9 Kai L, Schurig-Briccio LA, Feng X. et al Multi-target drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014; 57: 3126-3139
• 10 Wei L, Obregσn-Henao A, Wallach JB. et al Therapeutic potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrob Agents Chemother 2016; 60: 5198-5207
• 11 Heinrich N, Dawson R, du Bois J. et al Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015; 70: 1558-1566
• 12 Vlachou M, Siamidi A, Diamantidi E. et al. In vitro controlled release from solid pharmaceutical formulations of two new adamantane aminoethers with antitubercular activity. Drug Res 2017; 67 10.1055/s-0042-121491
• 13 Foscolos AS, Papanastasiou I, Tsotinis A et al. Synthesis of adamantane aminoethers with antitubercular potential. Med Chem. 2017 in press
• 14 Lipinski CA, Lombardo F, Dominy BW. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26
• 15 Komersova A, Lochar V, Myslıkova K. et al. Formulation and dissolution kinetics study of hydrophilic matrix tablets with tramadol hydrochloride and different co-processed dry binders. Eur J Pharm Sci 2016; 96: 36-45
• 16 Van Nguyen H, Nguyen VH, Lee BJ. Dual release and molecular mechanism of bilayered aceclofenac tablet using polymer mixture. Int J Pharm 2016; 515: 233-244
• 17 Lamoudi L, Chaumeil JC, Daoud K. Swelling, erosion and drug release characteristics of Sodium Diclofenac from heterogeneous matrix tablets. J Drug Deliv Sci Tech 2016; 31: 93-100
• 18 Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int J Pharmaceut 1993; 97: 1-3
• 19 Ritger P, Peppas N. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Controlled Rel 1987; 5: 37-42
• 20 Maestro, version 10.2, Schrödinger, LLC, New York, NY, 2015
• 21 LigPrep, version 3.4, Schrödinger, LLC, New York, NY, 2015
• 22 QikProp, version 4.4, Schrödinger, LLC, New York, NY, 2015
• 23 Jaguar, version 9.1, Schrodinger, Inc., New York, NY, 2016.
• 24 Shah VP, Tsong Y, Sathe P. et al. In vitro dissolution profile comparison–statistics and analysis of the similarity factor, f₂ . Pharm Res 1998; 15: 889-896
• 25 Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13: 123-133
• 26 Suzuki S, Green PG, Bumgarner RE. et al. Benzene Forms Hydrogen Bonds with Water. Science 1992; 257: 942-945